2026 Q1 -tulosraportti
73 päivää sitten
‧43 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 t sittenI wonder what they paid (phase 2b stage)? https://www.curiumpharma.com/2026/08/10/curium-acquires-abscint/
Just for fun, I asked Google for its guess. So total AI!! If I were to make an educated guess on the price for Curium's acquisition of Abscint SA, my estimate would be between 30 and 75 million euros (approx. 225 - 560 million DKK) in total transaction value, including the so-called "milestone" payments. Here are the most important factors and assumptions on which I base this guess: 📊 Rationale for the estimateEarly stage with high risk: Abscint's primary asset, ABS-011, is in Phase 2b testing. Because the product is not yet approved for sale, the buyer rarely pays large billion amounts up-front. The risk that the product fails in the final tests is still present. Previous financing as a benchmark: Abscint raised a financing round of 3 million euros in 2023 to cover the Phase 2 studies. A young biotech company at this stage is typically acquired for a value 10 to 20 times greater than their latest capital raising. Typical deal structure: In this type of medical acquisition, Curium will likely only pay a smaller portion in cash here and now (e.g., 10-20 million euros). The rest of the amount will only be paid out if ABS-011 achieves success in the Phase 3 tests and is finally approved by the authorities.
·6 t sittenIt seems that we are gradually staying at this level, or what are people's impressions?
Yes, it should be around this level. With current market cap. of approx. 700 mill I can quite easily imagine it quickly coming back to around 20 - 22 kr. Per Share.
·3 päivää sitten · MuokattuHas anyone else wondered a bit about the wording: “Increasing the lowest number of patients to be included to allow for at least 6 patients dosed with uTREAT® without blood-brain barrier disruption.” The critical detail is the wording “increasing the lowest number” – not “adding a new cohort of 6 patients.” This suggests that patients already exist in this category in the current dataset which they now wish to expand. Of course, there can be other interpretations. But protocol documents are extremely precisely formulated. Every word is thought through by clinical, legal, and regulatory experts. “Increasing the lowest number” is hardly just a poor formulation – it is a legal description of what is actually happening. “Adding a new cohort of at least 6 patients without mannitol” – that would mean that no such patients exist yet. “Increasing the lowest number of patients to be included to allow for at least 6 patients dosed without BBB disruption” – that means that there are already patients in this category, and that the minimum requirement for this group is being increased. (This thread is not a buy or sell recommendation - just a dialogue about what the protocol change really means - we need to get the ultimate answer from Curasight)
It should work without mannitol. The UTrace study has shown that the peptide binds to the tumor, and I don't think mannitol was used there to open the blood-brain barrier. The blood-brain barrier does not prevent radiation from passing. So, therefore, the tumor will be irradiated. The question is probably just how much? That is, how much of the utreat/peptide passes the barrier. I think they have been uncertain about that, and therefore introduced mannitol in the first place. That is at least my interpretation. Please correct me if I'm talking nonsense. Happy Sunday out there 🔥
·3 päivää sittenIt's really bad communication too, the preliminary results are nothing.. and then they change protocol without disclosing results of the primary study.. One fears a bit that mannitol is damaging something since they want to get rid of it and don't report anything.. if that's the case then brain cancer is a failed strategy.. Have written it before.. they are really bad at leading and communicating.. Still believe in the day.. but as I said when it was at 24.. one should sell the whole damn thing and re-enter later.. because they are really some fuckheads.. But I'm from the countryside.. here you don't sell ... you buy..One can always discuss that the communication should have been better, but in my head, the whole process makes relatively good sense. These upcoming data are the most important in Curasight's history, and thus it is important to obtain the best possible data. Therefore, they have introduced mannitol to ensure the best possible uptake of Utreat. Since they received additional capital in June (20 Mill dkk), they have assessed that the cheapest and fastest option would be to continue the ongoing study to gain the best possible knowledge about the uptake of Utreat in preparation for phase II trials. Opening the blood-brain barrier with mannitol is not without risk and can cause complications. It is used, for example, if chemotherapy is to be administered. So the complications are known. Thus, it makes good sense to try to remove mannitol, given that they have seen good data from the first 6-12 patients. The whole thing has come a bit late, but they only received additional capital in mid-June, so it makes sense that they have launched this extension here in July due to the extra capital and preparation time for updating the protocol.
·6.8.I must say that people are pulling out of this case, and the same with Flouguide. Have they lost faith due to the repeated postponements/changes of the study with longer response times and perhaps a need for new capital, could it be that's what one should do???And it's also only approx. 0.2% of the shares that are traded daily - so many holdings still believe in the technology
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
73 päivää sitten
‧43 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenI wonder what they paid (phase 2b stage)? https://www.curiumpharma.com/2026/08/10/curium-acquires-abscint/Just for fun, I asked Google for its guess. So total AI!! If I were to make an educated guess on the price for Curium's acquisition of Abscint SA, my estimate would be between 30 and 75 million euros (approx. 225 - 560 million DKK) in total transaction value, including the so-called "milestone" payments. Here are the most important factors and assumptions on which I base this guess: 📊 Rationale for the estimateEarly stage with high risk: Abscint's primary asset, ABS-011, is in Phase 2b testing. Because the product is not yet approved for sale, the buyer rarely pays large billion amounts up-front. The risk that the product fails in the final tests is still present. Previous financing as a benchmark: Abscint raised a financing round of 3 million euros in 2023 to cover the Phase 2 studies. A young biotech company at this stage is typically acquired for a value 10 to 20 times greater than their latest capital raising. Typical deal structure: In this type of medical acquisition, Curium will likely only pay a smaller portion in cash here and now (e.g., 10-20 million euros). The rest of the amount will only be paid out if ABS-011 achieves success in the Phase 3 tests and is finally approved by the authorities.
- ·6 t sittenIt seems that we are gradually staying at this level, or what are people's impressions?Yes, it should be around this level. With current market cap. of approx. 700 mill I can quite easily imagine it quickly coming back to around 20 - 22 kr. Per Share.
- ·3 päivää sitten · MuokattuHas anyone else wondered a bit about the wording: “Increasing the lowest number of patients to be included to allow for at least 6 patients dosed with uTREAT® without blood-brain barrier disruption.” The critical detail is the wording “increasing the lowest number” – not “adding a new cohort of 6 patients.” This suggests that patients already exist in this category in the current dataset which they now wish to expand. Of course, there can be other interpretations. But protocol documents are extremely precisely formulated. Every word is thought through by clinical, legal, and regulatory experts. “Increasing the lowest number” is hardly just a poor formulation – it is a legal description of what is actually happening. “Adding a new cohort of at least 6 patients without mannitol” – that would mean that no such patients exist yet. “Increasing the lowest number of patients to be included to allow for at least 6 patients dosed without BBB disruption” – that means that there are already patients in this category, and that the minimum requirement for this group is being increased. (This thread is not a buy or sell recommendation - just a dialogue about what the protocol change really means - we need to get the ultimate answer from Curasight)It should work without mannitol. The UTrace study has shown that the peptide binds to the tumor, and I don't think mannitol was used there to open the blood-brain barrier. The blood-brain barrier does not prevent radiation from passing. So, therefore, the tumor will be irradiated. The question is probably just how much? That is, how much of the utreat/peptide passes the barrier. I think they have been uncertain about that, and therefore introduced mannitol in the first place. That is at least my interpretation. Please correct me if I'm talking nonsense. Happy Sunday out there 🔥
- ·3 päivää sittenIt's really bad communication too, the preliminary results are nothing.. and then they change protocol without disclosing results of the primary study.. One fears a bit that mannitol is damaging something since they want to get rid of it and don't report anything.. if that's the case then brain cancer is a failed strategy.. Have written it before.. they are really bad at leading and communicating.. Still believe in the day.. but as I said when it was at 24.. one should sell the whole damn thing and re-enter later.. because they are really some fuckheads.. But I'm from the countryside.. here you don't sell ... you buy..One can always discuss that the communication should have been better, but in my head, the whole process makes relatively good sense. These upcoming data are the most important in Curasight's history, and thus it is important to obtain the best possible data. Therefore, they have introduced mannitol to ensure the best possible uptake of Utreat. Since they received additional capital in June (20 Mill dkk), they have assessed that the cheapest and fastest option would be to continue the ongoing study to gain the best possible knowledge about the uptake of Utreat in preparation for phase II trials. Opening the blood-brain barrier with mannitol is not without risk and can cause complications. It is used, for example, if chemotherapy is to be administered. So the complications are known. Thus, it makes good sense to try to remove mannitol, given that they have seen good data from the first 6-12 patients. The whole thing has come a bit late, but they only received additional capital in mid-June, so it makes sense that they have launched this extension here in July due to the extra capital and preparation time for updating the protocol.
- ·6.8.I must say that people are pulling out of this case, and the same with Flouguide. Have they lost faith due to the repeated postponements/changes of the study with longer response times and perhaps a need for new capital, could it be that's what one should do???And it's also only approx. 0.2% of the shares that are traded daily - so many holdings still believe in the technology
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
2026 Q1 -tulosraportti
73 päivää sitten
‧43 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenI wonder what they paid (phase 2b stage)? https://www.curiumpharma.com/2026/08/10/curium-acquires-abscint/Just for fun, I asked Google for its guess. So total AI!! If I were to make an educated guess on the price for Curium's acquisition of Abscint SA, my estimate would be between 30 and 75 million euros (approx. 225 - 560 million DKK) in total transaction value, including the so-called "milestone" payments. Here are the most important factors and assumptions on which I base this guess: 📊 Rationale for the estimateEarly stage with high risk: Abscint's primary asset, ABS-011, is in Phase 2b testing. Because the product is not yet approved for sale, the buyer rarely pays large billion amounts up-front. The risk that the product fails in the final tests is still present. Previous financing as a benchmark: Abscint raised a financing round of 3 million euros in 2023 to cover the Phase 2 studies. A young biotech company at this stage is typically acquired for a value 10 to 20 times greater than their latest capital raising. Typical deal structure: In this type of medical acquisition, Curium will likely only pay a smaller portion in cash here and now (e.g., 10-20 million euros). The rest of the amount will only be paid out if ABS-011 achieves success in the Phase 3 tests and is finally approved by the authorities.
- ·6 t sittenIt seems that we are gradually staying at this level, or what are people's impressions?Yes, it should be around this level. With current market cap. of approx. 700 mill I can quite easily imagine it quickly coming back to around 20 - 22 kr. Per Share.
- ·3 päivää sitten · MuokattuHas anyone else wondered a bit about the wording: “Increasing the lowest number of patients to be included to allow for at least 6 patients dosed with uTREAT® without blood-brain barrier disruption.” The critical detail is the wording “increasing the lowest number” – not “adding a new cohort of 6 patients.” This suggests that patients already exist in this category in the current dataset which they now wish to expand. Of course, there can be other interpretations. But protocol documents are extremely precisely formulated. Every word is thought through by clinical, legal, and regulatory experts. “Increasing the lowest number” is hardly just a poor formulation – it is a legal description of what is actually happening. “Adding a new cohort of at least 6 patients without mannitol” – that would mean that no such patients exist yet. “Increasing the lowest number of patients to be included to allow for at least 6 patients dosed without BBB disruption” – that means that there are already patients in this category, and that the minimum requirement for this group is being increased. (This thread is not a buy or sell recommendation - just a dialogue about what the protocol change really means - we need to get the ultimate answer from Curasight)It should work without mannitol. The UTrace study has shown that the peptide binds to the tumor, and I don't think mannitol was used there to open the blood-brain barrier. The blood-brain barrier does not prevent radiation from passing. So, therefore, the tumor will be irradiated. The question is probably just how much? That is, how much of the utreat/peptide passes the barrier. I think they have been uncertain about that, and therefore introduced mannitol in the first place. That is at least my interpretation. Please correct me if I'm talking nonsense. Happy Sunday out there 🔥
- ·3 päivää sittenIt's really bad communication too, the preliminary results are nothing.. and then they change protocol without disclosing results of the primary study.. One fears a bit that mannitol is damaging something since they want to get rid of it and don't report anything.. if that's the case then brain cancer is a failed strategy.. Have written it before.. they are really bad at leading and communicating.. Still believe in the day.. but as I said when it was at 24.. one should sell the whole damn thing and re-enter later.. because they are really some fuckheads.. But I'm from the countryside.. here you don't sell ... you buy..One can always discuss that the communication should have been better, but in my head, the whole process makes relatively good sense. These upcoming data are the most important in Curasight's history, and thus it is important to obtain the best possible data. Therefore, they have introduced mannitol to ensure the best possible uptake of Utreat. Since they received additional capital in June (20 Mill dkk), they have assessed that the cheapest and fastest option would be to continue the ongoing study to gain the best possible knowledge about the uptake of Utreat in preparation for phase II trials. Opening the blood-brain barrier with mannitol is not without risk and can cause complications. It is used, for example, if chemotherapy is to be administered. So the complications are known. Thus, it makes good sense to try to remove mannitol, given that they have seen good data from the first 6-12 patients. The whole thing has come a bit late, but they only received additional capital in mid-June, so it makes sense that they have launched this extension here in July due to the extra capital and preparation time for updating the protocol.
- ·6.8.I must say that people are pulling out of this case, and the same with Flouguide. Have they lost faith due to the repeated postponements/changes of the study with longer response times and perhaps a need for new capital, could it be that's what one should do???And it's also only approx. 0.2% of the shares that are traded daily - so many holdings still believe in the technology
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt